The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of paclitaxel-carboplatin-bevacizumab (PCB) with or without nitroglycerin patches (NTG) in patients (pts) with stage IV nonsquamous non-small cell lung cancer (NSCLC): Nvalt 12 (NCT01171170).
Anne-Marie C. Dingemans
No relevant relationships to disclose
Harry J.M. Groen
No relevant relationships to disclose
Judith Herder
No relevant relationships to disclose
Jos Stigt
No relevant relationships to disclose
Egbert F. Smit
No relevant relationships to disclose
Idris Bahce
No relevant relationships to disclose
Otilia Dalesio
No relevant relationships to disclose
Sjaak A. Burgers
No relevant relationships to disclose
Henk Codrington
No relevant relationships to disclose
BEN VAN Den Borne
No relevant relationships to disclose
Bonne Biesma
No relevant relationships to disclose
Andrew D. Vincent
No relevant relationships to disclose
Vincent van de Noort
No relevant relationships to disclose
Joachim Aerts
No relevant relationships to disclose